StockpollyBeta
Get App
Popularity #1,992
MBX · NASDAQ · Biotechnology

M.B.X. Biosciences (MBX)

Develops precision peptide therapies for endocrine and metabolic disorders.

$58.75
vs last close−3.23 (−5.21%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000000000
Gross profit000000000000
111013172019272224262741
Research & development9811141715221819201831
2222334456910
General & administrative2222334456910
Operating income−11−10−13−17−20−19−27−22−24−26−27−41
111113322444
Interest income111113322−744
Other non-operating income−1−3−1−1−1−3−3−2−2−4−40
Income before tax−10−9−12−16−18−16−24−19−22−22−24−37
Net income from continuing operations−10−9−12−16−18−16−24−19−22−22−24−37
Net income−10−9−12−16−18−16−24−19−22−22−24−37
EPS, basic−$0.32−$0.28−$0.37−$0.48−$0.54−$0.47−$0.71−$0.58−$0.63−$0.49−$0.50−$0.78
EPS, diluted−$0.32−$0.28−$0.37−$0.48−$0.54−$0.47−$0.71−$0.58−$0.63−$0.49−$0.50−$0.78
Weighted average shares, basic323233333333333334374748
Weighted average shares, diluted323233333333333334374748
EBITDA−10−7−12−16−18−16−24−19−22−22−23−41
Depreciation & amortization000000000000
EBIT−10−7−12−16−18−16−24−19−22−22−24−41